Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival.
Saved in:
| Title: | Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival. |
|---|---|
| Authors: | Perrone, Elisabetta1,2,3 (AUTHOR) elisabetta.perrone@guest.policlinicogemelli.it, Calcagni, Maria Lucia2,3 (AUTHOR), Leccisotti, Lucia2,3 (AUTHOR), Moretti, Roberto4 (AUTHOR), Ghai, Kriti1 (AUTHOR), Eismant, Aleksandr1,2 (AUTHOR), Parkar, Tanay1,3 (AUTHOR), Greifenstein, Lukas1,4 (AUTHOR), Baum, Richard Paul1 (AUTHOR) |
| Source: | Cancers. Sep2025, Vol. 17 Issue 18, p3070. 16p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 20726694 |
|---|---|
| DOI: | 10.3390/cancers17183070 |
